Update_Layout 1 - The British Society for Rheumatology

Transcription

Event update | 1
Your invitation to the
UK’s leading rheumatology conference
Create your own personalised programme online
www.rheumatology.org.uk/programme
Event update | 2
Join your colleagues at
Rheumatology 2012 | 1-3 May 2012
Invitation
We do hope that you are planning to join us at
Rheumatology 2012 in Glasgow. The conference is the
UK’s leading rheumatology event and offers an invaluable
chance for colleagues to come together to learn, network
and hear about the latest developments in the field.
We are all working in an increasingly challenging
environment and so it is more important than ever that we
come together as a community to support each other and
raise the profile of the specialty.
We hope to see you in Glasgow,
Prof David L Scott and Mrs Lindsey Hawley
What people thought
about Rheumatology 2011
96% of delegates would recommend
the conference to a colleague
87% say the conference is a key date
in their professional calendar
96% of delegates learnt something new
82% of doctors/allied health professionals
would change their practice following
the conference
Register now! www.rheumatology.org.uk/conference | 3
Key information
Why should I attend?
Rheumatology 2012 is focused on best practice in
rheumatology. Sessions are designed with clear aims
and outcomes, leading to effective and valuable learning
opportunities for the whole rheumatology team.
What will I get out of the conference?
At the conference you will:
Learn about recent developments in the field of
rheumatology
Explore all aspects of rheumatology including
osteoarthritis, osteoporosis, sports medicine, clinical
trials, psoriatic arthritis, pain, primary care, work,
CTD and basic science
Be inspired by keynote lectures, debates, interactive
sessions, poster tours, meet the experts and workshops
Gain accreditation from the RCP and RCN
Network with the whole rheumatology team
Learn about the latest research from oral and poster
abstracts
Meet colleagues from around the world and exchange
ideas and advice
Gain support for revalidation
Discuss commissioning and NHS changes
Attend dedicated streams for trainees, allied health
professionals and scientists
Who should attend?
Our varied conference programme appeals to all
healthcare professionals with an interest in rheumatology:
Consultant rheumatologists
Doctors in training
Nurse specialists
GPs
Academics
Physiotherapists
Researchers
Scientists
Students
Occupational therapists
Podiatrists
Industry professionals
Venue
SECC, Exhibition Way
Glasgow G3 8YW
Rheumatology 2012 will be held at the award winning
SECC. This iconic building, symbolising the city of Glasgow
and the regeneration of the river Clyde, offers state of the
art conference facilities, extensive exhibition space and a
four star hotel (the Crowne Plaza) all under one roof.
Getting there
Steeped in history and shaped by culture and innovation,
Glasgow has much to offer delegates, not least its
excellent transport links to the rest of the UK and abroad.
The closest international airport is just 15 minutes from
the city centre and Glasgow Central station offers direct
rail connections to many UK cities.
For full details of transport options, visit the SECC’s
website at www.secc.co.uk/attend.aspx
Accommodation
Rheumatology 2012 delegates can use the services of
our accommodation agent, Reservation Highway, to take
advantage of specially negotiated room rates. We have
secured an allocation at a variety of hotels across the city,
to suit all budgets. Early booking is highly recommended bookings made after 2 April 2012 will be subject to
availability and a higher price. Booking can be done
online via www.rheumatology.org.uk/accommodation
NEW! Create your conference schedule
With so many high quality sessions on offer, make sure
you make the most of your time at the conference with
our online programme planner. View the details of the
sessions on offer and build your own conference diary
which you can then print off or email. Go to
www.rheumatology.org.uk/programme to start planning
your time at the UK’s leading rheumatology conference.
Early bird registration deadline: Friday 3 February 2012
Event update | 4
Keynote speakers
Tuesday 1 May, 14.00 – 16.00
Keynote: Jewels in the crown
Sir Philip Craven, President International
Paralympic Committee
Sir Philip Craven is a five time
Paralympian in Wheelchair Basketball
(1972-1988) and Swimming (1972).
His international achievements in
Wheelchair Basketball include World
championship/Gold Cup (1973), Gold
medal – European Championship (1991
and 1994) and Bronze medal – World
Championship/Gold Cup (1975). Sir Philip has also received a
number of prestigious awards including Knight Bachelor by HM
Queen Elizabeth II for services to Paralympic Sport (2005) and
Member of the Order of the British Empire (MBE) by HM Queen
Elizabeth II for services to Wheelchair Basketball (1991).
Sir Philip is the current President of the International
Paralympic Committee. His major contributions to Paralympic
sport include Member of the International Olympic Committee
(IOC) (since 2003), Member of the Executive Board, British
Olympic Association (since 2003), Board Member of the London
2012 Organizing Committee for the Olympic and Paralympic
Games (since 2005) and Member of the IOC Commission for
Culture and Olympic Education (since 2005). Sir Philip Craven’s
professional career has included Performance Director, GBWBA
Men’s Wheelchair Basketball Team (1998-2002), Chief
Executive Officer, International Wheelchair Basketball Federation
(1994-1998) and Company Secretary, British Coal Corporation
(Western Area) (1986-1991).
Tuesday 1 May, 11.30 – 13.00
Droitwich Lecture
Dr Jackie Hill, Senior Lecturer in Rheumatology,
University of Leeds, Leeds
Jackie has worked in rheumatology for
over 30 years as a practitioner, a
senior lecturer and a researcher. She
was one of the first rheumatology nurses
in the UK to hold nurse led clinics and
undertook the seminal research into
outcomes from these clinics. She
obtained her Masters Degree in 1991,
her PhD in 2000 and in 1990 was honoured with Fellowship of
the Royal College of Nursing for an outstanding contribution to
the science and art of rheumatology nursing. Jackie is a former
Chair of the RCN Rheumatology Nursing Forum, President of
BHPR and has sat on several EULAR committees. More recently
she was co-convenor of the EULAR Nursing Task Force which
published Recommendations for the Basic and Advanced Role of
the Nurse in the Management of Chronic Inflammatory Arthritis.
Before her retirement in July 2011 she was co-director of the
Academic and Clinical Unit for Musculoskeletal Nursing, a reviewer
for ten journals and a grant application reviewer for six national
bodies including NIHR. Jackie was the Associate Editor of
Musculoskeletal Care and editor/author of three books and ten
book chapters. She has published over 130 papers and has given
numerous presentations and keynote lectures at national and
international conferences.
Tuesday 1 May, 16.30 – 17.30
Heberden Round
Prof Philip Conaghan, Professor of Musculoskeletal
Medicine, University of Leeds, Leeds
Professor Conaghan’s major research
interests are in understanding pathogenesis
and therapeutic response in osteoarthritis
and rheumatoid arthritis, with a special
focus on the role of imaging. His research
incorporates a spectrum from translational
and proof-of-concept work through to large
clinical trials. He is Professor of
Musculoskeletal Medicine at the University of Leeds, and Chairs the
NICE OA Guidelines Development Group and Arthritis Research UK’s
OA Clinical Studies Group. He previously chaired the Assessment of
Structural Change Working Group of the OARSI-FDA OA Initiative.
He recently completed his term as inaugural Chair of the EULAR
Standing Committee on Imaging, is leader for the OMERACT
Imaging & Biomarkers workstream and is President of the
International Society for Musculoskeletal Imaging in Rheumatology.
He has authored over 250 papers, book chapters and books.
Wednesday 2 May 16.45 – 17.45
Heberden Oration
Prof Paul Wordsworth, Professor of Rheumatology and
Consultant Rheumatologist, Nuffield Department of
Orthopaedics, Rheumatology and Musculoskeletal
Sciences, Oxford
Professor Wordsworth works in the NIHR
Oxford Musculoskeletal Biomedical
Research Unit. His clinical and research
interests are particularly oriented towards
understanding the genetic basis of
musculoskeletal diseases. These include
monogenic disorders, such as Marfan
syndrome and skeletal dysplasias, but also
complex polygenic inflammatory arthropathies. He is a co-founder
of the international consortium investigating the genetics of
ankylosing spondylitis that identified the association with IL23R
and ERAP1. His group also helped to solve the crystal structure of
ERAP1 in 2011. He is co-author of Clinical and Biochemical
Disorders of the Skeleton and has published over 300 original
scientific papers, mainly on the genetics of rheumatic diseases.
He is a Fellow of Green Templeton College.
Rheumatology 2012 programme
Our conference programme is always extremely well evaluated by delegates and
we are always striving to deliver high quality content in new and accessible ways.
Here are just some of the highlights of this year’s event.
Essentials in rheumatology:
Our Essentials symposium, now in its third year, has
established itself as a valuable feature of the conference.
Popular amongst consultants and trainees alike, it serves to
support revalidation and draws from the whole rheumatology
curriculum over a cycle of five years. This year’s Essentials will
explore three broad areas: disease management; symptoms
diagnosis; and clinical decision making, with interactive,
case-based sessions on ankylosing spondylitis and vasculitis.
Allied health professionals:
A packed programme. Highlights include a demonstration of
the key features of NHS Evidence, an overview of initiatives to
reduce work absence for people with musculoskeletal
conditions, exploration of the management of inflammatory
arthritis and back pain and how therapies can be targeted to
improve musculoskeletal pain. There will also be a session
providing delegates with indispensable advice on how to get
their work accepted as a conference abstract.
Pages 15, 19 and 22
Pages 9, 11, 16, 20, 21, 22, 26, 29 and 31
Trainee stream:
2011’s inaugural Rheumatologists at Training symposium was
an outstanding success. A dedicated programme for trainees
organised by trainees, this year’s symposium will provide
updates on the political and the clinical - changes in the NHS
and how they affect rheumatology, the clinical teaching of
spondyloarthropathies and discussion of the evidence-based
approach to myopathies. This symposium is a must for
trainees.
Primary care:
This year’s primary care programme aims to increase
communication between hospital rheumatologists and the
primary care team. Delegates will explore the difficulties in
diagnosing and differentiating between rheumatological
conditions and associated problems. In addition to this the
role and contribution of allied health professionals working in
primary care and the implications of commissioning
changes will be explored.
Pages 27, 29 and 31
Pages 16, 18, 19, 22 and 23
NHS changes:
2011 was a year of turbulence in the health service for many.
We need to revisit the way that we plan and deliver
musculoskeletal services in order to demonstrate quality
improvement and patient satisfaction. ARMA will be
highlighting the changes and innovations that are taking place
in England and the devolved nations. Commissioning and the
provision of these new services require a new skill set and the
trainee and primary care programmes together with the ARMA
update will encourage debate and discussion.
Sports medicine:
London 2012 puts sports medicine firmly on the agenda for
our event of the same year. The conference features an
overview of the challenges faced by modern sport and
exercise medicine practice, highlighting how sports and
exercise medicine and rheumatology will be able to
interact to provide optimal medical care. In addition to this,
our ‘Jewels of the Crown’ session will feature Sir Philip Craven
MBE, President of the International Paralympic Committee
(IPC) giving a unique keynote address.
Pages 16, 19 and 31
Pages 11 and 14
Basic science:
Back by popular demand, this year’s science symposium will
give attendees an overview and understanding of key issues
in the molecular mechanisms of rheumatological pathologies.
Current views of osteoarthritis and inflammatory arthritis will
be discussed and delegates will be updated on novel
laboratory research in each area from both students and
experts in the field.
Accreditation
The RCP have awarded Rheumatology 2012
18 CPD points
Pages 26, 29, 31 and 32
Rheumatology 2012 has also been accredited 19 study
hours by the Royal College of Nursing Accreditation Unit
Event update | 6
Sessions
Delegates are free to attend any sessions on the days for
which they have registered (subject to room capacity).
Tuesday:
Session
BHPR
Oral abstracts
Special interest group
Keynote session
Industry supported symposium
Networking event
Wednesday:
Session
Essentials in rheumatology
BHPR
Oral abstracts
Keynote session
Networking event
Thursday:
Science
Trainee
Auto immune diseases
BHPR
Oral abstracts
Note: programme is subject to change at this stage.
Tuesday 1 May 2012
09.30 - 10.30
Reproductive issues in rheumatology
8
Clinical trials to advance the development of new therapies
8
Hypermobility - overmedicalised? A debate
8
BHPR: Physical activity and exercise in inflammatory arthritis
9
Oral abstracts: Spondyloarthropathies
9
SIG: BHPR Connective tissue disease
SIG: Lung disease in rheumatoid arthritis
9
10
10.30 - 11.30 Poster viewing and exhibition | Tea and coffee
11.30 - 13.00
INBANK, BSR Registers and the new information age
10
Sport and exercise medicine
11
Sex discrimination in the autoimmune rheumatic diseases
11
BHPR: Droitwich Lecture, Lifetime achievement award and Prizes 11
Oral abstracts: Imaging
12
SIG: Polymyalgia rheumatica and giant cell artertis
12
SIG: RA outcomes
13
13.00 - 14.00 Exhibition | Lunch
13.00 - 14.00
BHPR AGM
13
BHPR Post Graduate Research Student Network
13
BSRBR open meeting
13
14.00 - 16.00
Jewels in the Crown
14
16.00 - 16.30 Exhibition | Tea and coffee
16.30 - 17.30
Heberden Round
14
17.30 - 18.00
Industry supported symposia catering
14
18.00 - 19.30
Industry supported symposium: Pfizer Inc
14
19.45 - 21.00
Presidents’ reception
14
Wednesday 2 May 2012
07.30 - 09.00
Industry supported symposia: Bristol-Myers Squibb and
Cellestis GmbH
Thursday 3 May 2012
15
07.30 - 09.00
Industry supported symposium: Abbott
25
SIG: Myositis
25
09.15 - 10.45
Essentials: Disease management
15
09.00 - 10.30
Science: Molecular mechanisms of disease: osteoarthritis
26
Mimickers of myositis and treatment update
16
Optimising therapy for rheumatoid arthritis
26
Osteoporosis: topical issues
16
26
BHPR: Primary care rheumatology: leading the way
16
BHPR: Pain and motor function: mechanisms and treatment
approaches
Oral abstracts: RA treatments and outcomes
17
Trainee: Interactive quiz and clinical teaching
27
SIG: MSK health in multi ethnic minorities
17
Oral abstracts: Epidemiology
27
SIG: Genetics of inflammatory arthritis
17
SIG: Sjögren’s syndrome
27
SIG: Scleroderma
18
SIG: MSK ultrasound
28
19
11.30 - 13.00
Advances in psoriatic arthritis
28
ARMA: Devolution of health: what can we learn?
19
Science: Molecular mechanisms of disease: inflammatory
29
Rheumatological challenges in primary care
19
Trainee: Ask the experts: myositis
29
BHPR plenary orals
20
arthritis I
Oral abstracts: Connective tissue diseases
20
29
SIG: Vasculitis
20
BHPR: The management of upper limb dysfunction in people
with rheumatoid arthritis
SIG: Paediatric and adolescent rheumatology
21
Oral abstracts: Education
30
SIG: Osteoporosis
30
SIG: Foot and ankle
30
11.45 - 13.15
Essentials: Symptom diagnosis and management
13.15 - 14.45
BSR AGM
BHPR: How to get your abstract published
21
21
14.45 - 16.15
Essentials: Keeping up to date, clinical decision making
22
BHPR: Current thinking on conservative management of
back pain
22
Juvenile-onset SLE and childhood scleroderma
22
Recent advances in osteoarthritis therapy
22
13.00 - 14.00
Trainee: RATs AGM
31
BHPR: NICE and NHS Evidence and the information revolution 31
14.00 - 15.30
Science: Molecular mechanisms of disease: inflammatory
arthritis II
31
Trainee: Rheumatology and the NHS
31
31
BHPR: Improving work participation: new developments in
reducing work absence for people with musculoskeletal conditions
Oral abstracts: Primary Care
23
23
What’s new in ankylosing spondylitis pathogenesis,
assessment and treatment
32
SIG: Heritable disorders of connective tissue
SIG: BHPR Rheumatoid arthritis
23
Oral abstracts: Genetics
32
16.15 - 16.45 Exhibition | Tea and coffee
16.45 - 17.45
Heberden Oration
24
17.45 - 18.00
24
18.00 - 19.30
Industry supported symposia: Roche and Abbott
24
20.00 - Late
Conference dinner and Ceilidh
24
SIG: Education
33
SIG: Osteoarthritis
33
15.00 - 17.00
SIG: Spondyloarthropathy
33
17.00 End of meeting
Event update | 8
Tuesday 1 May 2012
Session | BHPR | Oral abstracts | Special interest group | Keynote session | Industry symposium | Networking event
09.00 - 10.30
Aim:
Outcome 1:
Outcome 2:
Outcome 3:
09.00
09.20
09.40
10.00
09.00 - 10.30
Aim:
Outcome 1:
Outcome 2:
09.00
09.25
09.50
10.20
09.00 - 10.30
Aim:
Outcome 1:
Outcome 2:
Outcome 3:
09.00
09.20
09.40
10.00
Reproductive issues in rheumatology: do you know how to advise your patients?
Chairs: Prof Ian Giles, UCL, London | Prof Caroline Gordon, University of Birmingham, Birmingham
To provide delegates with up to date knowledge of the issues surrounding rheumatological
conditions and drugs in conception, pregnancy, and lactation
Delegates will be aware of the current state of knowledge amongst rheumatologists and
obstetricians surrounding the safe use of rheumatological drugs in conception, pregnancy
and lactation
Delegates will be aware of the need for a national consensus on the use of rheumatological
drugs in conception, pregnancy and lactation, and how such a consensus can be achieved
Delegates will have a better understanding of the complications in pregnancy associated
with rheumatological conditions
Is pregnancy a stress test for subsequent development of autoimmunity?
Dr David Williams, UCLH, London
Drugs in conception, pregnancy, and lactation: towards a national consensus
Dr Munther Khamastha, St Thomas’ Hospital, London
Are biologics safe in pregnancy?
Prof Monika Østensen, Sörlandet Hospital, Kristiansand
Rheumatological conditions in pregnancy and the puerperium
Prof Catherine Nelson-Piercy, Guy’s and St Thomas’ Hospitals Trust, London
Clinical trials to advance the development of new therapies
Chair: Dr Duncan Porter, Gartnavel General Hospital, Glasgow
This session is to inform rheumatologists about performing clinical trials in rheumatoid arthritis
Delegates will understand how stratified medicine and biomarkers can be applied to improve
therapeutic responses in patients
Delegates will understand the influence of genetics on responses observed in clinical trials
Conducting clinical trials in rheumatoid arthritis: practicalities and potential pitfalls
Prof Paul Emery, University of Leeds, Leeds
Stratified medicine and biomarkers
Prof Mahesh Parmar, UCL, London
Design, analysis and reporting of pharmacogenetic studies
Prof Anne Barton, University of Manchester, Manchester
Discussion
Hypermobility: overmedicalised? A debate
Chairs: Prof Howard Bird | Prof Anthony Redmond, University of Leeds, Leeds
To transparently debate key controversial aspects of our diagnosis and management of child and adult joint
laxity/hypermobility (as currently defined); this should inform clinical and academic future direction
Delegates will gain an understanding of evidence underpinning management and learn new
epidemiological data
Delegates will Participate in healthy discussion on pros and cons of current diagnosis and management
Delegates will decide which of the opposing viewpoints is most convincing
First proposition
Dr Jacqui Clinch, University of Bath, Bath
Second proposition
Prof Alan Silman, University of Manchester, Chesterfield
First opposition
Prof Rodney Grahame, UCL, London
Second opposition
Dr Alan Hakim, Whipps Cross University Hospital, London
09.00 - 10.30
Aim:
Outcome 1:
Outcome 2:
Outcome 3:
09.00
09.25
09.50
09.00 - 10.30
9.00
9.15
9.30
9.45
10.00
10.15
09.00 - 10.30
Aim:
Outcome 1:
Outcome 2:
Outcome 3:
09.00
09.20
09.40
10.00
10.20
Physical activity and exercise in inflammatory arthritis
Chairs: Dr Fiona Cramp, University of the West of England, Bristol | Dr Claire Goodchild,
King’s College London, London
To provide an overview of the role of physical activity and exercise in the management of
inflammatory arthritis
Attendees will understand the effects of physical activity and exercise in those with inflammatory
arthritis
Attendees will understand the current UK physical activity guidelines, the uptake and physical
activity preferences in people with rheumatic diseases
Attendees will consider the implementation of a home based physical activity programme for
people with inflammatory arthritis
Exercise for rheumatoid arthritis patients
Dr Andrew Lemmey, Bangor University, Gwynedd
Implementation of a physical activity programme for people with rheumatoid arthritis using
motivational interviewing
Dr Emalie Hurkmans, Leiden University Medical Centre (LUMC), Leiden, The Netherlands
Physical inactivity in rheumatic diseases
Ms Victoria Manning, King’s College London, London
Oral abstracts: Spondyloarthropathies
Detecting axial spondyloarthritis (ASpA) amongst primary care back pain referrals
Mrs Claire Harris, Northwick Park Hospital, Harrow
Validation of a screening questionnaire for axial SpA in a UK population
Dr Karl Gaffney, Norfolk and Norwich University Hospital, Norwich
The prevalence and burden of ankylosing spondylitis in Europe: a systematic review
Ms Linda Morton, University of Aberdeen, Aberdeen
Work disability in established psoriatic arthritis: a cross sectional study using the work productivity
activity index (WPAI)
Dr Willi Tillett, Royal National Hospital for Rheumatic Diseases, Bath
Influence of leflunomide on the levels of matrix metalloproteinase-3 (MMP-3) and pyridinoline (PYR) in
patients with psoriatic arthritis (PsA)
Dr Dmytro Fedkov, Kiev National Medical, Kyiv, Ukraine
Evaluation of efficacy and safety of secukinumab in the treatment of patients with moderate-to-severe
ankylosing spondylitis
Dr Wolfgang Hueber, Novartis Institutes for BioMedical Research, Basel, Switzerland
BHPR SIG: Connective tissue disease
To provide an overview of the complexities of disease presentations and management approaches
in scleroderma, including digital ulcer disease and pulmonary hypertension
To gain an understanding of the diagnostic process for those with scleroderma, including
management and treatment options
To become aware of the significance of digital ulcer disease in scleroderma, its impact on the
patient and the supportive role of the nurse specialist
To gain an understanding of the importance of a multi-disciplinary approach in effective and early
diagnosis, treatment and management of scleroderma associated lung and cardiac disease
Diagnosing scleroderma and treatment options, the role of the rheumatologist
Dr John Pauling, Royal National Hospital for Rheumatic Diseases NHS Foundation Trust, Bath
Managing digital ulcers and supporting patients with scleroderma, the role of the clinical
nurse specialist
Mrs Sue Brown, Royal National Hospital for Rheumatic Diseases NHS Foundation Trust, Bath
Lung and pulmonary vascular disease in scleroderma, the role of the specialist pulmonary physician
Dr Jay Suntharalingham, Royal United Hospital, Bath
Cardiac and pulmonary vascular disease in scleroderma, the role of the specialist cardiologist
Dr Gerry Coghlan, Royal Free Hospital NHS Foundation Trust, London
Questions
Event update | 10
Tuesday 1 May 2012
09.00 - 10.30
Aim:
Outcome 1:
Outcome 2:
Outcome 3:
09.00
09.30
10.00
10.30 - 11.30
SIG: Lung disease in rheumatoid arthritis
To update on progress with the National Database of interstitial lung disease in RA, educate on
relationship between pulmonary infection and RA and inform members of the latest data on the
effects of anti rheumatic drugs and the lung
To ensure that delegates are aware of the national database for ILD in RA and understand how to
enter patients into this
To educate delegates about the growing body of evidence linking both acute and chronic pulmonary
infection with morbidity and mortality in RA
To update delegates with the latest data on the effects of the newer biologic agents on the lung
in patients with RA
The National Database for patients with interstitial lung disease in rheumatoid arthritis: an update
Dr Clive Kelly, Queen Elizabeth Hospital, Gateshead
The relationship between bronchiectasis, anti CCP antibody and rheumatoid arthritis
Dr Elizabeth Perry, Royal Cornwall Hospital, Truro
Safety and efficacy of rituximab in patients with rheumatoid arthritis and interstitial lung disease
Dr Shouvik Dass, St James Hospital, Leeds
Poster viewing and exhibition | Tea and coffee
Categories:
BHPR
Imaging
Metabolic and crystal arthropathies
Miscellaneous rheumatic diseases
Rheumatoid arthritis: clinical features
Rheumatoid arthritis: comorbidities
Scleroderma and related disorders
Spondylarthropathies (including psoriatic arthritis)
11.30 - 13.00
Aim:
Outcome 1:
Outcome 2:
Outcome 3:
11.30
11.50
12.10
12.30
12.50
Poster tours:
BHPR
Rheumatoid arthritis
Spondyloarthropathies
INBANK, BSR Registers and the new information age
Chairs: Prof Deborah Bax, Royal Hallamshire Hospital, Sheffield | Prof David L Scott, King’s
College London, London
To inform the membership about new and emerging data resources in rheumatology, and to raise
awareness of the opportunities afforded by the establishment of INBANK as a national resource for
clinical data linkage to biological samples and NHS outcomes
Understand the value of national data resources in rheumatology and raise awareness of datasets
including the newly established ankylosing spondylitis biologics register and the national joint register
Understand how INBANK will function and allow clinicians both to audit their own clinical performance
Allow participants to ask questions about key issues including consent, access, security and resources
Advances in drug information in rheumatic disease: the ankylosing spondylitis register
Prof Gary Macfarlane, University of Aberdeen, Aberdeen
The power of data linkage: lessons from the National Joint Register
Prof Alex MacGregor, University of East Anglia, Norwich
INBANK: a national musculoskeletal information platform
Prof Alan Silman, Arthritis Research UK, Chesterfield
INBANK in practice
Dr William Dixon, University of Manchester, Manchester
Discussion
11.30 - 13.00
Sport and exercise medicine
Chairs: Prof Nicola Maffulli, Queen Mary University of London, Barts and the London School of Medicine and
Dentistry, London | Dr Roger Wolman, Royal National Orthopaedic Hospital, London
Aim:
Outcome 1:
To provide delegates an overview of the challenges faced by modern sport and exercise medicine practice
Delegates will be able to identify the key issues concerning modern sport and exercise medicine
practice, and discuss these in an open, interactive session
Delegates will be aware of how these issues may affect rheumatology in the future
Delegates will have a better understanding of how sports and exercise medicine and
rheumatology will be able to interact to provide optimal medical care
Outcome 2:
Outcome 3:
11.30
11.35
11.55
12.15
12.40
11.30 - 13.00
Aim:
Outcome 1:
Outcome 2:
Outcome 3:
11.30
11.55
12.10
12.25
12.40
11.30 - 13.00
11.30
12.15
12.20
British sport and exercise medicine: a five minute history of a specialty
Prof Nicola Maffulli, Queen Mary University of London, Barts and the London School of Medicine and
Dentistry, London
Exercise: a unique therapeutic intervention for primary, secondary and tertiary disease prevention.
Let’s all prescribe it!
Dr Christopher Hughes, Queen Mary University of London, Barts and the London School of Medicine and
Dentistry, London
Anterior cruciate ligament reconstruction: good for your knee?
Prof Anthony Bull, Imperial College London, London
Platelet-rich plasma in musculoskeletal medicine: some truths
Dr Umile Giuseppe Longo, University Campus Biomedico, Rome, Italy
Taking care of tender tendons
Prof Nicola Maffulli, Queen Mary University of London, Barts and the London School of Medicine and
Dentistry, London
Why can’t a man be more like a woman? Sex discrimination in autoimmune rheumatic diseases
Chairs: Prof David Isenberg, University College London Hospital, London | Dr Patrick Gordon, King’s College
Hospital, London
To provide a thought provoking session on the evident disparity in the prevalence, causes and
consequences of autoimmune rheumatic disease (ARDs) involvement between men and women
To achieve a better understanding of the disparity and differential effects of ARDs on men and women
To achieve a better understanding of the links between the immune and endocrine systems
To achieve a better understanding of whether hormonal manipulation might play a part in the
therapy of ARDs
Endocrine influences on the immune system
Dr Betty Diamond, Feinstein Institute Medical Research, New York, USA
Male lupus: the Loch Ness monster syndrome revisited
Prof David Isenberg, University College London Hospital, London
Rheumatoid arthritis in men
Prof John Isaacs, University of Newcastle, Newcastle Upon Tyne
Scleroderma in men
Prof Christopher Denton, Royal Free Hospital, London
Blocking female hormones: smart or stupid?
Prof Anisur Rahman, University College London Hospital, London
Droitwich Lecture, Lifetime achievement award and Prizes
Chair: Mrs Lindsey Hawley, President BHPR
Rheumatology nursing: a journey of discovery
Dr Jackie Hill, Senior Lecturer in Rheumatology Nursing, University of Leeds, Leeds
Lifetime achievement award
Dr Jackie Hill, Senior Lecturer in Rheumatology Nursing, University of Leeds, Leeds
Prize ceremony
Event update | 12
Tuesday 1 May 2012
11.30 - 13.00
11.30
11.45
12.00
12.15
12.30
12.45
11.30 - 13.00
Aim:
Outcome 1:
Outcome 2:
Outcome 3:
11.30
11.45
12.00
12.15
12.30
12.45
Oral abstracts: Imaging
Hand osteoarthritis pain has peripheral and central components demonstrated by algometer scores
and functional MRI
Dr Nidhi Sofat, St George’s, University of London, London
Ultrasound features of osteophytes and cartilage thickness at the knee are associated with pain
and functional impairment: the Newcastle thousand families study
Dr Ajay Abrah, Newcastle University, Newcastle upon Tyne
The diagnostic utility of salivary gland ultrasound for the investigation of sjögren’s syndrome
Dr Andrew Carr, Newcastle Dental Hospital, Newcastle upon Tyne
Long-term radiographic outcome in psoriatic arthritis patients treated with Golimumab: 104 week
results from the go-reveal study
Dr Chandrabhusan Chattopadhyay, Wrightington Hospital, Wigan
Early effect of Secukinumab in reducing spinal inflammation as detected by magnetic resonance
imaging in patients with ankylosing spondylitis
Prof Jaap Van Laar, Newcastle University, Newcastle upon Tyne
Tocilizumab as monotherapy or in combination with methotrexate associated with early reductions in
tissue inflammation: 12 week results from a magnetic resonance imaging substudy of a randomized
controlled trial
Prof Philip Conaghan, University of Leeds, Leeds
SIG: Polymyalgia rheumatica and giant cell artertis
To increase awareness of the attendees of advances in the diagnosis, guidelines on management,
clinical trials, biomarkers and patient support in PMR and GCA
Attendees will learn about the EULAR ACR Classification Criteria for PMR and the approach to
differentiate PMR from other conditions that present with a polymyalgic syndrome
Attendees will learn about the management of PMR and GCA in PMR and development of
pathways to improve diagnosis and reduce ischemic complications
Attendees will learn about the status of ongoing clinical trials in PMR, GCA and large vessel vasculitis
PMR Classification Criteria
Prof Bhaskar Dasgupta, Southend University Hospital, Southend
Pathways and management of PMR and GCA in primary care
Prof Christian Mallen, Keele University, Keele
Clinical trials in PMR, GCA and large vessel vasculitis
Prof Carlo Salvarani, Azienda Ospedaliera Arcispedale Santa Maria Nuova Reggio Emilia, Italy
Annexin and its receptor in PMR and GCA
Prof Mauro Perretti, St Barts Hospital, London
Development of a patient support organisation for PMR and GCA
Dr Kate Gilbert, Chair, PMRGCAUK
Discussion
11.30 - 13.00
Aim:
Outcome 1:
Outcome 2:
Outcome 3:
11.30
11.50
12.10
12.30
12.50
SIG: RA outcomes
To discuss topical & recent issues in management & outcomes of early RA by leaders in this field
Understand the many facets of pain in RA
Appreciate the importance of joint failure in RA as measured by orthopaedic surgery
Debate the different perspectives proposed for DAS28 cut offs for biological therapy
Pain in early RA: inflammatory or central sensitisation?
Prof David Walsh, The University of Nottingham, Nottingham
Orthopaedic interventions for RA: clinical and health economic aspects
Dr Elena Nikiphorou, Norfolk and Norwich University Hospital, Norwich and Prof Steve Morris, UCL, London
DAS28 criteria for initiation of biologics in early RA: a clinician’s view
Dr Patrick Kiely, St George’s Hospital, London
DAS28 criteria for initiation of biologics in early RA: NICE perspectives
Dr Chris Deighton, Derby Hospitals NHS Trust, Derby
Discussion
13.00 - 14.00
Exhibition | Lunch
13.00 - 14.00
BHPR AGM
Join your colleagues over lunch and meet BHPR Council members to hear what they have been doing on your
behalf and how they plan to meet the challenges of the year ahead. Your attendance, which is highly valued,
automatically enters you into the prize draw for a chance to win free registration to the 2013 conference in
Birmingham.
13.00 - 14.00
BSRBR open meeting
13.00 - 14.00
BHPR Post Graduate Research Student Network: a practical guide to post-doctoral career
progression
Chairs: Dr Michael Backhouse, University of Leeds, Leeds | Ms Lindsay Hooper, University of Southampton,
Southampton
Aim:
Outcome 1:
Outcome 2:
Outcome 3:
13.00
13.05
13.25
To provide a coordinated network for early career researchers that facilitates peer group discussion
and support from a range of leading academics
Attendees will be able to identify the key steps in developing post-doctoral careers
Attendees will gain practical tips on developing collaborative networks, managing funding portfolios
and structuring programs of research
Attendees will have the opportunity to discuss the lecture content with peers and senior
academics, facilitating the opportunity to develop their own collaborative links
Introduction from the chair
Dr Michael Backhouse, Leeds Musculoskeletal Biomedical Research Unit, Leeds
Post-PhD career planning
Prof Nadine Foster, Keele University, Keele
Facilitated group discussion
Prof Sarah Hewlett and Dr Tessa Sanderson, University of West of England, Bristol
Event update | 14
Tuesday 1 May 2012
14.00 - 16.00
14.00
14.20
14.40
15.00
15.20
15:40
Jewels in the crown
Chairs: Prof David L Scott, President BSR | Mrs Lindsey Hawley, President BHPR
London 2012 Olympic Games: keynote lecture
Sir Phillip Craven MBE, President of the International Paralympic Committee (IPC)
Michael Mason prize winner: Silver standard: measuring treatment effects using observational data
Dr Kimme Hyrich, University of Manchester, Manchester
Garrod Prize winner: The relationship between pregnancy and long-term functional disability in women
with inflammatory polyarthritis: results from the Norfolk Arthritis Register (NOAR)
Mrs Elizabeth Camacho, University of Manchester, Manchester
Epidemiology of sporting injuries on elite soccer players: a longitudinal study
Mr Philip Cooper, MRC Lifecourse Epidemiology Unit, Southampton
Epratuzumab demonstrates clinically meaningful improvements in patients with moderate to severe
systemic lupus erythematosus (SLE): results from Emblem™, a phase IIB study
Prof Caroline Gordon, University of Birmingham, Birmingham
Will I waste your time? Delays in help-seeking for RA flares
Ms Caroline Flurey, University of the West of England, Bristol
16.00 - 16.30
Exhibition | Tea and coffee
16.30 - 17.30
Heberden Round: The new rheumatoid arthritis
Prof Philip Conaghan, Chair of Musculoskeletal Medicine, University of Leeds, Leeds
17.30 - 18.00
18.00 - 19.30
Industry supported symposia: Pfizer
19.45 - 21.00
Presidents’ reception
The Presidents of BSR and BHPR invite you to join them at this dedicated networking event at the nearby
Crowne Plaza hotel which will provide the perfect opportunity to meet and continue your discussions with
rheumatology colleagues and industry peers in a relaxed and informal setting.
Drinks and canapés will be provided | This event is free to attend for registered delegates
Session | Essentials in rheumatology | BHPR | Oral abstracts | Special interest group | Keynote session
Industry supported symposium | Networking event
07.30 - 09.00
Industry supported symposia:
Cellestis GmbH
Bristol-Myers Squibb
Getting it right: optimising RA treatment strategies in the evolving NHS
Chair: Prof Philip Conaghan, University of Leeds, Leeds
Aim:
Outcome 1:
Outcome 2:
Outcome 3:
Conclusion:
09.15 - 10.45
Aim:
Outcome:
09.15
09.45
10.15
To educate delegates on how they can tailor biologic treatment choices in rheumatoid arthritis (RA) to
deliver value both for patients and the NHS, in context of the evolving NHS (QIPP, QoF). To deliver an
update on the differing mode of actions of biologic therapy, examining whether the different MOA’s
available offer different outcomes for patients. The session will also explore the current theories/research
into the RA patient profiling, and show how tailoring biologic therapy can offer better outcomes for the
patient whilst delivering value to the NHS
Delegates will have a better understanding of how the NHS changes (White Paper, QIPP agenda) could
affect the role of the rheumatologist and specialist RA services. Highlighting the need for services to be
able to demonstrate the best outcomes for patients, whilst driving efficiencies
Delegates will have an update into the current research that is taking place into patient profiles/subtypes
in RA and how these can be used to deliver better outcomes
Delegates will understand how using a tailored approach to biologic therapy can improve patient
outcomes/demonstrate value to the NHS, within the framework of currently available NICE guidance
The new NHS and rheumatology: what does the future hold?
Dr Mark Davies, RES Consortium and Dr P Kiely, St George’s Healthcare NHS Trust, London
Is MOA of biologics important when choosing an RA treatment?
Prof Iain McInnes and Prof Paul Garside, University of Glasgow, Glasgow
Patient profiling in RA: what do we know? Where are we heading?
Dr Andrew Östör, Addenbrooke’s Hospital, Cambridge
Tailoring biologic treatment to patient profiles in RA
Dr Josef S Smolen, University of Vienna, Vienna, Austria
To conclude the meeting there will be closing remarks from the Chairperson, followed by a panel Q&A to
draw conclusions on the session as a whole
Essentials in Rheumatology: Disease management
Chairs: Prof John Axford, St George’s Hospital, London | Dr Charles Mackworth-Young, Charing Cross
Hospital, London
A comprehensive update covering everything you need to know about changes in rheumatology
To prepare rheumatologists for revalidation and provide a valuable educational opportunity for trainees
Delegates will have been brought up to date on disease management
Metabolic bone diseases
Prof Juliet Compston, University of Cambridge, Cambridge
Psoriatic arthritis
Prof Oliver Fitzgerald, St Vincent’s University Hospital, Dublin
Antiphosphlipid syndrome
Prof Anisur Rahman, UCL, London
Event update | 16
09.15 - 10.45
Aim:
Outcome 1:
Outcome 2:
Outcome 3:
09.15
09.45
10.15
09.15 - 10.45
Aim:
Outcome 1:
Outcome 2:
Outcome 3:
09.15
09.40
10.05
10.30
09.15 - 10.45
Outcome 1:
Outcome 2:
Outcome 3:
09.15
09:40
10.05
10.30
Mimickers of myositis and treatment update: room for improvement and lessons from neurology
Chair: Dr Robert Cooper, Hope Hospital, Manchester
To provide delegates with an overview of the issues surrounding misdiagnosis in myositis and an update in
best practice
Delegates will be able to identify the key factors in securing a diagnosis of metabolic/mitochondrial myopathy
or dystrophy and excluding inflammatory myopathy
Delegates will have a better understanding of the key clinical features in inclusion body myositis, how the
diagnosis may be missed and current management strategies
Delegates will receive an update on current best practice in the management of myositis
Adult onset metabolic/mitochondrial myopathies and dystrophies: how these cases can be missed
Dr Mark Roberts, Salford Royal NHS Foundation Trust, Salford
Inclusion body myositis and misdiagnosis of polymyositis
Prof Michael Hanna, National Hospital for Neurology and Neurosurgery, London (to be confirmed)
Treatment update and best practice in inflammatory myopathy
Prof Chester Oddis, Arthritis Institute, Pittsburgh, USA
Osteoporosis: topical issues
Chair: Dr Emma Clark, University of Bristol, Bristol
To provide general rheumatologists and trainees with an update on topical issues in osteoporosis
To understand the association between calcium/vitamin D supplementation and cardiovascular outcomes
To discuss ways of maximising adherence with bisphosphonates
To highlight how recent advances in genetics of High Bone Mass could impact on clinical practice
Should we stop regular prescribing of calcium/vitamin D supplementation because of the risk of
adverse cardiovascular outcomes?
Prof Bo Abrahamsen, University of Southern Denmark, Odense, Denmark
Bisphosphonates: what can we do to maximise adherence?
Prof Rob Horne, University of London, London
Applying recent insights in causes of High Bone Mass to clinical practice
Dr Celia Gregson, University of Bristol, Bristol
Discussion
Primary care rheumatology: leading the way
Chairs: Dr Louise Warburton, NHS Telford and Wrekin, Telford | Ms Melanie Holden, Keele University, Keele
Delegates will gain an understanding of models of established primary care based musculoskeletal services
Delegates will have an awareness of the role and contribution of allied health professionals working
in primary care
Delegates will explore the implications of commissioning changes for allied health professionals
Primary care led rheumatology services
Dr Jill Firth, Pennine Musculoskeletal Partnership, Oldham
Musculoskeletal interface clinics: how physiotherapy has contributed to this model of care
Mrs Kay Stevenson, Haywood Hospital, Stoke on Trent
Business planning for a patient centred rheumatology service
Mrs Ann Todd, Pennine Musculoskeletal Partnership, Oldham
Discussion
09.15 - 10.45
9.15
9.30
9.45
10.00
10.15
10.30
09.15 - 10.45
Aim:
Outcome 1:
Outcome 2:
Outcome 3:
09.15
09.45
10.15
09.15 - 10.45
Aim:
Outcome 1:
Outcome 2:
Outcome 3:
09.15
09.35
09.55
10.15
10.35
Oral abstracts: RA treatment and outcomes
Validation of JADAS in all subtypes of juvenile idiopathic arthritis (JIA) in the clinical setting
Dr Flora McErlane, University of Manchester, Manchester
Has orthopaedic intervention for RA changed in line with combination and anti-TNF therapies?
An evaluation of joint surgery rates and prognostic factors in two UK inception cohorts (1986-2011)
ERAS/ERAN
Dr Elena Nikiphorou, St Albans City Hospital, St Albans
Predicting responses to anti-TNFα therapy in patients with rheumatoid arthritis using metabolomic
analysis of urine
Dr Sabrina Kapoor, University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust,
Birmingham
Doubleblind study of Tocilizumab + Methotrexate vs Tocilizumab + placebo in patients with active
rheumatoid arthritis despite prior Methotrexate: progression of structural dage, quality of life,
and physical function at 24 weeks
Prof Maxime Dougados, Paris-Descartes University, Cochin Hospital, Paris, France
Secukinumab treatment provides sustained response over one year in patients with rheumatoid arthritis
Dr Patrick Durez, Université Catholique de Louvain, Louvain, Belgium
Withdrawal of Adalimumab in early rheumatoid arthritis patients who attained stable low disease activity
with Adalimumab plus Methotrexate: results of a phase 4, double-blind, placebo-controlled trial
Prof Paul Emery, Leeds Teaching Hospital, Leeds
SIG: MSK health in multi ethnic minorities
To develop awareness of health issues in multi ethnic minorities with special emphasis on MSK health
To understand the global issues on multi ethnic minority health issues
To develop programmes of research and audit
To develop strategy of improving the health care with special emphasis on MSK health
Global health issues in multi ethnic minority: UK perspective
Dr Sonya Fernandez, Kent University, Canterbury
What research should be done in minority communities and how to publish
Dr Kamran Abbasi, The Royal Society of Medicine, London
Taking patient education into newer immigrant communities
Ms Chandrika Gordhan, University of Birmingham, Birmingham
SIG: Genetics of inflammatory arthritis
To illustrate how advances in the understanding of the genetic basis of rheumatic diseases may
impact clinically
The attendees will understand the role of genetic markers in risk prediction and how this is being
applied in the clinical setting
Delegates will appreciate that treatment response is multi-factorial and will understand that genetics,
environmental, host factors and epigenetics all play a role
Novel approaches to analysis of outcome will be described with reference to juvenile idiopathic arthritis
Using genetics to inform risk prediction in RA
Dr Sophia Steer, King’s College Hospital, London
Predicting treatment response
Prof Anne Barton, The University of Manchester, Manchester
The role of epigenetics in prediction of treatment response
Prof Gerry Wilson, The University of Sheffield, Sheffield
Translation of genetic studies into prediction of outcome in JIA
Prof Wendy Thomson, The University of Manchester, Manchester
Panel discussion
Event update | 18
09.15 - 10.45
Aim:
Outcome 1:
Outcome 2:
Outcome 3:
09.15
09.30
09.45
10.00
10.15
10.30
10.45 - 11.45
SIG: Scleroderma
To discuss some of the challenging areas of management of systemic sclerosis and present consensus
best practice pathways that have been developed over the past 18 months by scleroderma centres in the
UK. This is a major initiative of the UK scleroderma study group (UKSSG) that has developed draft
consensus pathways for digital vasculopathy and for gastrointestinal complications of scleroderma
(systemic sclerosis).
Appreciation of multi-disciplinary definition of the domains of major clinical involvement of the
gastrointestinal tract in scleroderma.
Understanding the interplay between upper and lower limb vasculopathy leading to complications of
secondary Raynaud’s phenomenon in scleroderma.
Challenges in early detection of systemic sclerosis and appropriate stratification of cases for high intensity
treatment such as immunosuppression with stem cell rescue
Development of expert consensus best practice management for systemic sclerosis: a UK scleroderma
study group (UKSSG) initiative
Prof Chris Denton, UCL Medical School/Royal Free Hospital, London
Gastrointestinal tract manifestations of systemic sclerosis
Dr Charles Murray, Royal Free Hospital, London
Complications of scleroderma vasculopathy: Raynaud’s phenomenon, digital ulcers and critical digital
ischaemia
Prof Ariane Herrick, Salford Royal Hospital and University of Manchester, Manchester
Impact of high intensity immunosuppression on vasculopathy and gastrointestinal tract disease in
systemic sclerosis - is global disease modification possible?
Dr Madolon Vonk, Nijmegen University Medical Centre, Nijmegen, Netherlands
Early diagnosis of scleroderma: prevention rather than treatment.
Secondary Raynaud’s and risk stratification by autoantibody profile
Prof Neil McHugh, Royal National Hospital for Rheumatic Diseases, Bath
Discussion
Categories:
Poster tours:
Muscle disorders
Osteoarthritis
Orthopaedics and rehabilitation
Rheumatoid arthritis: treatment
Osteoarthritis
Osteoporosis and metabolic bone disease
Paediatric and adolescent rheumatology
Primary care
Psychology, measurement and management of pain
Rheumatoid arthritis: treatment
Soft tissue and regional musculoskeletal disease, fibromyalgia
11.45 - 13.15
11.45
12.15
12.45
11.45 - 13.15
Aim:
Outcome 1:
Outcome 2:
Outcome 3:
Outcome 4:
11.45
12.00
12.25
12.50
11.45 - 13.15
Aim:
Outcome:
11.45
12:15
12.45
ARMA session
Devolution of health: what can we learn?
Chair: Prof David Marsh, UCL, London
Focus on Scotland
Dr Sarah Mitchell, National Programme Manager for the Delivery Framework for Adult Rehabilitation,
Greater Glasgow and Clyde
This project has three key work areas:
1) Multi professional MSK care pathways
2) A pilot using NHS 24 telephony to provide a national advice triage service to signpost to information
and local MSK services
3) Embedding working health services Scotland in all MSK pathways
Focus on England: Taking forward the MSK networks and an update on commissioning activity
Prof David Marsh, UCL, London and Mrs Laura Guest, CEO British Society for Rheumatology
Focus on Wales
Speaker to be confirmed
Rheumatological challenges in primary care
Chair: Dr Elspeth Wise, Encompass Healthcare, Washington
To provide delegates with an understanding of difficulties in diagnosing rheumatological conditions and
associated problems in primary care
Awareness of how frequently rheumatological problems present in primary care
Understanding of how to diagnose early inflammatory arthritis in primary care
Increased knowledge of co-morbidity associated with polymyalgia rheumatica
Understanding of how to differentiate inflammatory back pain from other causes of low back pain in
primary care
What musculoskeletal problems does the average GP see?
Dr Mark Porcheret, Arthritis Research UK Primary Care Centre, Keele
How to better diagnose early inflammatory arthritis in primary care
Dr Karim Raza, University of Birmingham, Birmingham
Polymyalgia rheumatica: more than just shoulder pain
Prof Christian Mallen, Arthritis Research UK Primary Care Centre, Keele
Seeing the wood for the trees: diagnosing inflammatory back pain in primary care
Prof Ingemar Petersson, Skane University Hospital, Lund, Sweden
Essentials in rheumatology: symptom diagnosis and management
Hospital, London
A comprehensive update covering everything you need to know about changes in rheumatology
Delegates will have had the opportunity to discuss symptom diagnosis
Ocular manifestations of rheumatological disorders
Mr Carlos Pavesio, Moorfields Eye Hospital, London
Is there infection? Arthritis, bones and prosthetics
Prof Tony Berendt, Nuffield Orthopaedic Centre, Oxford
Improving patient management: what do patients want?
Prof Sir Gordon Duff, University of Sheffield, Sheffield
Event update | 20
11.45 - 13.15
11.45
12.00
12.15
12.30
12.45
13.00
11.45 - 13.15
11.45
12.00
12.15
12.30
12.45
13:00
11.45 - 13.15
Aim:
Outcome 1:
Outcome 2:
Outcome 3:
BHPR plenary orals
The impact of pain on successful ageing
Dr Ross Wilkie, Keele University, Keele
Forefoot bursae are a prognostic indicator of disabling foot complications in patients with RA: results of
a prospective three-year study
Ms Lindsey Hooper, University of Southhampton, Southampton
The continuing professional development for health professionals working within musculoskeletal
services: a national UK survey
Dr Jo Adams, University of Southampton, Southampton
Debridement of painful forefoot plantar callosities in rheumatoid arthritis: the CARROT randomised
controlled trial
Mrs Heidi Siddle, University of Leeds, Leeds
Psychological well-being in early rheumatoid arthritis: findings from the early rheumatoid arthritis
network (ERAN)
Dr S Norton, University of Cambridge, Cambridge
Health professionals’ perceptions of the effects of exercise on joint health in rheumatoid arthritis (RA)
patients II: a follow-up focus group study
Ms Serena Halls, Bangor University, Cardiff
Oral abstracts: Connective Tissue Diseases
Variability in the phenotype of metabolic syndrome over time in a multicentre international inception cohort
of patients with SLE
Dr Ben Parker, University of Manchester, Manchester
Nitrated nucleosome levels in patients with systemic lupus erythematosus: associations with ethnicity,
autoantibody status and disease activity
Dr Sara Croca, University College London, London
Is there an association between Warfarin and survival in SSC-PAH patients treated with first line bosentan
monotherapy?
Dr Clare Warrell, Royal Free Hampstead NHS Trust, London
ANTI-EIF2 is associated with interstitial lung disease in patients with systemic sclerosis
Dr Zoe Betteridge, Royal National Hospital for Rheumatic Diseases, Bath
Optical coherence tomography validation: a new quantitative imaging biomarker for affected skin in scleroderma
Dr Giuseppina Abignano, Leeds Institute of Molecular Medicine, Leeds
The clinical relevance of ANTI-RO52 and ANTI-RO60 in patients in the United Kingdom primary sjögren’s
syndrome registry (UKPSSR)
Dr Josephine Vila, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Sunderland
SIG: Vasculitis
To provide an update on current areas of research in systemic vasculitis, emphasising the potential
for attendees to take an active role
To gain an understanding of the diverse research projects curently conducted in systemic vasculitis
To understand the evidence base for current management in systemic vasculitis (including emerging
diagnostic tests and therapeutics)
To enable attendees to take an active role in vasculitis studies now and in the future
11.45
12.00
12.15
12.30
12.45
13.00
11.45 - 13.15
Aim:
Outcome 1:
Outcome 2:
Outcome 3:
11.45
12.05
12.25
12.45
13.05
Quality of life in ANCA associated vasculitis (VASQoL study findings)
Dr Neil Basu, University of Aberdeen, Aberdeen
Update on developing diagnostic and classification criteria in systemic vasculitis (DCVAS)/
Update on the temporal artery biopsy vs ultrasound study (TABUL)
Dr Joanna Robson and Prof Raashid Luqmani, University of Oxford, Oxford
Use of the General Practice Research database in vasculitis: focus on aortic aneurysm risk in GCA
Prof Nigel Arden, University of Oxford, Oxford
European Vasculitis Study Group (EUVAS) therapeutic trials in vasculitis where have we got to and where
are we going?
Dr David Jayne, Addenbrooke’s Hospital, Cambridge,
Genome wide association studies in ANCA associated vasculitis
Dr Richard Watts, University of East Anglia, Ipswich
Panel discussion
SIG: Paediatric and adolescent rheumatology
To focus on the changing role of paediatric and adult rheumatologists in the care of young people,
including discussion of the drivers and barriers for change and consumer involvement
Delegates will have discussed how we ensure adult services provide rheumatologists with appropriate
skills and experience to take on the care of young people
Delegates will have addressed how we engage young people / consumers in their care and
involving them in research
Delegates will have fedback on what they would like the paediatric and adolescent SIG to achieve in the future
Standards of care for children and young people with JIA
Dr Eileen Baildam, Alder Hey Hospital, Liverpool
Changing role of adult rheumatologists in paediatric and adolescent care
Prof Helen Foster, Newcastle University, Newcastle upon Tyne
Adolescent training Issues and RCP involvement
Dr Rachel Tatterall, Sheffield Teaching Hospitals NHS Trust, Sheffield
Involving young people in rheumatology research
Dr Janet McDonagh, Birmingham Children’s Hospital, Birmingham
Discussion
13.15 - 14.45
Exhibition | Lunch
13.15 - 14.45
BSR AGM
Join your colleagues over lunch and meet the Trustees and committee members of your society. Hear what they
have been doing on your behalf and how they plan to meet the challenges of the year ahead. Your attendance
is highly valued and lunch will be provided
13.15 - 14.45
How to get your abstract published
Chair: Ms Tricia Cornell, Poole Hospital NHS Foundation Trust, Poole
Aim:
Outcome 1:
Outcome 2:
Outcome 3:
13.15
13.35
To provide delegates with the tools to submit a quality abstract submission
Delegates will understand the key issues surrounding a quality abstract submission
Delegates will be able to critically analyse an abstract submission with a view to improving the quality
Delegates will be able to re-formulate an abstract to make a quality submission
Abstract review: what the reviewers are looking for in a quality abstract submission
Ms Tricia Cornell, Poole Hospital NHS Foundation Trust, Poole
Group work: Critically analyzing 2-3 abstracts
Ms Tricia Cornell, Poole Hospital NHS Foundation Trust, Poole | Ms Diana Finney, Sussex Community
NHS Trust, Brighton | Dr Sarah Ryan, Haywood Hospital, Stoke on Trent
Event update | 22
14.45 - 16.15
Aim:
Outcome 1:
Outcome 2:
Outcome 3:
14.45
15.05
15.25
15:45
Current thinking on conservative management of back pain
Chairs: Mrs Sue Gurden, Aneurin Bevan Health Board, Abergavenny | Prof Nadine Foster, Keele
University, Keele
To update delegates on current thinking on low back pain management
Delegates will have an increased knowledge of tools available to aid treatment selection in low back pain
in the clinic
Delegates will have an increased knowledge of health economics and it’s clinical application in treatment
selection and service delivery in low back pain
Delegates will have an increased knowledge of the influence of patient’s and practitioner’s health beliefs
on rehabilitation in low back pain
Can we choose the best treatment for back pain patients?
Dr Jonathan Hill, Keele University, Keele
Are back pain treatments cost-effective? What clinicians need to know about health economics
Dr Duncan Critchley, King’s College London, London
Low back pain in primary care
Prof Martin Underwood, University of Warwick, Coventry
The direct and indirect impact of health beliefs in low back pain on outcomes
Dr Tamar Pincus, University of London, Egham
14.45 - 16.15
Essentials in rheumatology: Keeping up to date, clinical decision making - what is the evidence?
Hospital, London
Put your clinical decision making to the test using interactive voting keypads
Aim:
Outcome:
Delegates will have had their clinical decision making skills tested
14.45
15.30
14.45 - 16.15
14.45
15:10
15.35
16.00
14.45 - 16.15
Aim:
Outcome 1:
Outcome 2:
Outcome 3:
Ankylosing spondylitis
Prof Roger Sturrock, Glasgow Royal Infirmary, Glasgow
Vasculitis
Dr David Jayne, University of Cambridge, Cambridge
Juvenile-onset SLE and childhood scleroderma: new insights into pathology, treatment and outcomes
Chairs: Dr Jacqui Clinch, University of Bath, Bath | Prof David Isenberg, UCL, London
What is the natural history of scleroderma with its onset in childhood?
Dr Eileen Baildam, Alder Hey Children’s NHS Foundation Trust, Liverpool
Why is it important to know about lupus in children?
Prof Michael Beresford, Alder Hey Children’s Foundation NHS Trust, Liverpool
Improving and optimising long term outcomes of patients with juvenile-onset SLE
Dr Clarissa Pilkington, Great Ormond Street Hospital, London
Panel discussion
Recent advances in osteoarthritis therapy
Chairs: Prof Philip Conaghan, University of Leeds | Dr George Peat, Keele University, Keele
To provide delegates with a state of the art update on the clinical management and structural
modification of OA
Understand the varying effectiveness of mechanical interventions in the clinical management and
structural modification of lower limb OA
Understand the therapeutic role and effectiveness of structural modifying drugs in OA
Gain understanding of joint distraction as a method of tissue modification in OA
14.45
15.05
15.25
15.45
14.45 - 16.15
14.45
15.00
15.15
15.30
15.45
14.45 - 16.15
Aim:
Outcome 1:
Outcome 2:
Outcome 3:
14.45
15.05
15.25
15.45
16.05
14.45 - 16.15
Aim:
Outcome 1:
Outcome 2:
Outcome 3:
Mechanical effectiveness of foot orthoses in OA
Mrs Jill Halstead, University of Leeds, Leeds
Varying effectiveness of mechanical interventions in knee OA
Dr Richard Jones, University of Salford, Salford
Tissue structure modification in late stage osteoarthritis is feasible
Prof Floris Lafeber, University Medical Center Utrecht, Utrecht, The Netherlands
Lecture to be confirmed
Oral abstracts: Primary Care
Audit to assess GP awareness and documentation of biologic and DMARD drugs in primary care patient
records
Dr Charlotte Goodhead, Queen Elizabeth Hospital Gateshead, Gateshead
The MRC physiodirect trial: a pragmatic randomised controlled trial of ‘physiodirect’ telephone
assessment and advice services versus usual care for musculoskeletal problems
Dr Annette Bishop, Keele University, Keele
Frequency of musculoskeletal symptoms and presenting complaints in video observed primary care
consultations with patients aged 45 and over
Dr Zoe Paskins, Arthritis Research UK Primary Care Centre, Keele
Deciding to consult the general practitioner for symptomatic osteoarthritis: a choice-based conjoint
analysis study
Ms Domenica Coxon, Keele University, Keele
Are rheumatoid arthritis patients screened for cardiovascular disease in primary care?
Ms Helen Monk, Keele University, Keele
SIG: Heritable disorders of connective tissue
Chair: Prof Howard Bird, University of Leeds, Leeds
To equip rheumatology clinicians with knowledge and understanding of the impact of chronic pain in
EDS/JHS and the evidence base for its alleviation by physical and cognitive interventions
Delegates will acquire a greater appreciation of the multi-systemic nature of EDS/JHS, including chronic
pain, dysautonomia and gastrointestinal dysmotility
Delegates will be able to offer a multidisciplinary strategy for the rehabilitation of patients with severe
deconditioning, reduced mobility and independence
Delegates will acquire a greater familiarity with new developments in relevant therapeutic modalities in
the published literature
Hypermobility, fibromyalgia and chronic pain
Dr Alan Hakim, Whipps Cross Hospital, London
Medical rehabilitation and pain control
Dr Helen Cohen, Royal National Orthopaedic Hospital, Stanmore
Physical rehabilitation: role of physiotherapy/OT
Rosemary Keer, Hospital of St John and St Elizabeth's, London
Cognitive interventions in EDS/JHS and chronic pain
Dr Clare Daniel, UCLH, London
Panel discussion
BHPR SIG: Rheumatoid arthritis
To hold a session on rheumatoid arthritis of interest to BHPR and BSR members. Topics to be covered are
tocilizumab therapy and early arthritis
Delegates will learn new information on tocilizumab therapy
Delegates will learn about the delays to presentation and treatment in RA
Delegates will have an opportunity to ask questions and participate in discussion on the topics presented
Programme to be confirmed
16.15 - 16.45
Exhibition | Tea and coffee
Event update | 24
16.45 - 17.45
Heberden Oration
Lessons in rheumatology from extreme phenotypes and subtle genotypes
Prof Paul Wordsworth, Professor of Rheumatology and Consultant Rheumatologist, Nuffield Department
of Orthopaedics, Rheumatology and Musculoskeletal Sciences
17.45 - 18.00
18.00 - 19.30
Industry supported symposia:
Abbott
The patient at the heart of Treat to Target
New practical tools to optimise the consultation process
Chair: Prof Paul Emery, Chapel Allerton Hospital, Leeds
18.00
18.05
18.20
18.50
19.15
19.25
Welcome and introduction
Prof Paul Emery, Chapel Allerton Hospital, Leeds
New initiatives to drive Treat to Target
Translating clinical targets into realistic personalised goals
Prof Peter Taylor, University of Oxford, Oxford
TRACK to optimise the consultation process
Dr Andrew Östör, Addenbrooke’s Hospital, Cambridge and Kate Gadsby, Rheumatology Nurse Specialist,
Derbyshire Royal Infirmary, Derby
Question and answer session
All speakers (facilitated by Prof Paul Emery)
Thank you and close
Roche
Assessing the evidence: the role of RoACTEMRA in the first-line treatment of rheumatoid arthritis
Chair: Prof Ernest Choy, Cardiff University, Cardiff
Welcome and introduction
Prof Ernest Choy, Cardiff University, Cardiff
Presenting the case: First-line use of Tocilizumab in rheumatoid arthritis – flawed or flawless?
Prof Ernest Choy, Cardiff University, Cardiff
Assessing the evidence: ‘Putting infections into perspective’
Prof John Isaacs, Newcastle University, Newcastle upon Tyne
Assessing the evidence: Cardiovascular risk and inflammatory lipids
Dr Naveed Sattar, University of Glasgow, Glasgow
Assessing the evidence: Neutrophil function in the inflammatory response, platelets and haematology
Haematologist speaker
Question and answers
Faculty
20.00 - Late
Conference dinner and Ceilidh
Join us for our networking dinner. Enjoy an unforgettable evening of traditional food, drink and entertainment at
Òran Mór, which appropriately means the ‘great melody of life’
The evening will begin at 20.00 and tickets are only £40 (Inc VAT). Book early to avoid disappointment
Thursday 3 May 2012
Science | Trainee | Auto immune diseases | BHPR | Oral abstracts | Special interest group
07.30 - 09.00
Industry supported symposium:
Abbott
Abbott Axial SpA symposium
Axial spondyloarthritis – augmenting diagnosis, management, and treatment
Chair: to be confirmed
07.30
07.40
08.00
08.20
08.40
08.55
07.30 - 09.00
Aim:
Outcome 1:
Outcome 2:
Outcome 3:
07.30
07.45
08.00
08.15
08.30
08.45
Welcome and Introduction
Session chair
Axial spondyloarthritis: distinguishing a presentation
Dr Helena Marzo Ortega, Leeds Musculoskeletal Biomedical Research Unit, Leeds
Improving diagnosis and management with MRI
Dr Alex Bennett, Defence Medical Rehabilitation Centre, Epsom
Treatment success in axial spondyloarthritis: ABILITY 1 results
Question and answer
Panel
Summary and close
Session chair
SIG: Myositis
To provide an update on pertinent issues in myositis and upcoming research/clinical activities
To discuss the latest investigations used in the diagnosis and differential diagnosis of myositis
To discuss current controversies in the management of inflammatory myositis
To gain an understanding of the research topics undertaken through UKMYONET
Update on Arthritis Research UK Clinical Studies Group involvement in CTDs
Professor David Isenberg, UCL, London
Update on antibody testing in inflammatory myopathy
Prof Neil McHugh, Royal National Hospital for Rheumatic Disease, Bath
Dr Harsha Gunawardena, North Bristol NHS Trust, Bristol
Standardisation of histopathological testing in myositis
Dr Patrick Gordon, King’s College Hospital, London
Treatment issues in myositis: case presentations and discussion
Dr Chris Edwards, Southampton University Hospitals NHS Trust, Southampton
Genome wide association studies in inflammatory myopathy and UK MYONET genetic study
Prof Robert Cooper, Salford Royal NHS Foundation Trust, Salford
Discussion
Event update | 26
Thursday 3 May 2012
09.00 - 10.30
Aim:
Outcome 1:
Outcome 2:
09.00
09.10
09.30
09.50
10.10
09.00 - 10.30
Aim:
Outcome 1:
Outcome 2:
Outcome 3:
09.00
09.25
09.50
10.15
09.00 - 10.30
Aim:
Outcome 1:
Outcome 2:
Outcome 3:
09.00
09.25
09.50
10.15
Molecular mechanisms of disease: osteoarthritis
To give attendees an overview and understanding of key issues in the molecular mechanisms of osteoarthritis
Delegates will be aware of current dogma of molecular pathogenesis in osteoarthritis
Delegates will be aware of novel laboratory research in osteoarthritis
Keynote talk on osteoarthritis
Dr Tonia Vincent, Imperial College London, London
Identification of novel osteoarthritis genes using Zebrafish
Dr Chrissy Hammond, University of Bristol, Bristol
Is adrenomedullin a potential therapeutic for osteoarthritis while its truncated peptide 22-52 acts as a
pro degenerative factor?
Dr Frédéric Velard, Lariboisière Hospital, Paris, France
Investigation of the role of UFM1 specific peptidase 2 in Beukes hip dysplasia
Mr Michal Dudek, University of Manchester, Manchester
Cannabidiol blocks the inhibitory effects of the GPR55 agonist L-alpha-lysophosphatidylinositol on
mechanosensitive knee joint afferents
Mr Kenneth Paton, University of Nottingham, Nottingham
Optimising therapy for rheumatoid arthritis
Chairs: Dr Maya Buch, University of Leeds, Leeds | Prof Michael Ehrenstein, UCL, London
Provide an update on new therapies in RA and how to more effectively use existing therapies to
achieve remission
Understand the principles of treat to target in RA
Appreciate how new therapies will fit into the current treatment pathway for RA
Update on the challenges and treatment of extrarticular manifestations of RA
Achieving tight control in RA
Prof Ronald Van Vollenhoven, Karolinska University Hospital, Stockholm, Sweden
New therapies for RA: is there room?
Dr Maya Buch, University of Leeds, Leeds
Extra-articular complications in RA: impact of biologic therapies and unmet patient need
Prof Ian Bruce, University of Manchester, Manchester
Panel discussion
Pain and motor function: mechanisms and treatment approaches
Chairs: Prof Mike Hurley, St George’s University of London, London | Dr Jane Hall, Royal National Hospital for
Rheumatic Diseases NHS Foundation Trust
To explain how pain interacts at the cortical and peripheral level with the sensorimotor system and
how therapies can be targeted to improve musculoskeletal pain using osteoarthritis as a model
Delegates will have a greater understanding of how chronic musculoskeletal pain interacts and
changes peripheral and central motor control systems
They will understand how these changes in function can be identified and explored in the clinical
research setting
Delegates will have a greater understanding of how therapies can be designed to reduce pain and
improve function in the community setting
Keeping control of function in the presence of pain: how does the brain cope?
Prof Candy McCabe, Royal National Hospital for Rheumatic Diseases, Bath and University of the West
of England, Bath
Changes in sensorimotor behavior with pain and how to capture these in a movement analysis laboratory
Prof Charlotte Hager, Umeå University, Umeå, Sweden
Developing effective and affordable community based interventions to improve osteoarthritic pain
and function
Dr Nicola Walsh, University of the West of England, Bristol
Discussion
09.00 - 10.30
Aim:
Outcome 1:
Outcome 2:
09.00
09:45
09.00 - 10.30
9.00
9.15
9.30
9.45
10.00
10.15
09.00 - 10.30
Aim:
Outcome 1:
Outcome 2:
Outcome 3:
09.00
09.20
09.40
10.00
10.20
Interactive quiz and clinical teaching
Chairs: Dr Ben Parker, University of Manchester, Manchester | Dr Sonia Panchal, University Hospital of
Leicester NHS Trust, Leicester
To review and update clinical teaching of spondyloarthropathies using interactive voting pads to
encourage participation
To review the spondyloarthropathies
To update clinical teaching
Psoriatic arthritis
Dr Philip Helliwell, University of Leeds, Leeds
Ankylosing spondylitis
Dr Andrew Keat, Northwick Park Hospital, Harrow
Oral abstracts: Epidemiology and Outcomes
The risk of solid cancer in patients receiving anti-tumour necrosis factor therapy for rheumatoid arthritis:
results from the British Society for Rheumatology Biologics Register
Dr Louise Mercer, The University of Manchester, Manchester
Systemic rheumatoid vasculitis in the biologic era
Dr Eleana Ntatsaki, Norfolk and Norwich University Hospital, Norwich
Incidence of rheumatoid arthritis in the UK using the 2010 ACR/EULAR classification criteria; and
comparison with estimates using the 1987 ACR criteria
Dr Jennifer Humphreys, University of Manchester, Manchester
Smoking and rheumatoid factor status in predicting responses to biologics
Dr Abdul Khan, King’s College Hospital, London
Breast is best. Lifecourse influences on the development of knee osteophytes: the Newcastle thousand
families study
Dr Ajay Abrah, Newcastle University, Prenton
Association of systemic sclerosis with different autoantibody subgroups and malignancies: a retrospective
registry-based UK cohort study
Dr Pia Moinzadeh, Royal Free Hospital, London
SIG: Sjögren’s syndrome
To review recent advances in oral diagnosis and ocular diagnosis, treatment and research in Sjögren’s
syndrome. To review current ongoing clinical research in Sjögren’s syndrome and discuss new initiatives
Participants will have updated their knowledge on the oral and ocular manifestations of Sjögren’s
syndrome
Participants will have been brought up to date on current research and current and future treatments
Participants will have received an update on the current multicentre studies
Sjögren’s: oral perspectives
Dr Gill Smith, Department of Oral Medicine at the Dental Hospital, Glasgow
Sjögren’s: the ophthalmology perspective
Mr Sanjay Mantry and Dr Ramesh Arora, General Hospital, Glasgow
Update on TRACTISS
Dr Simon Bowman, Queen Elizabeth Medical Centre, Birmingham
Update on UKPSSRS and future directions for Sjögren’s research
Dr Fai Ng, Newcastle University, Newcastle
Panel discussion
Event update | 28
Thursday 3 May 2012
09.00 - 10.30
Aim:
Outcome 1:
Outcome 2:
Outcome 3:
09.00
09.20
09.40
10.00
10.20
10.30 - 11.30
SIG: MSK ultrasound
To provide a platform to discuss and share research and training topics to further advance and promote
musculoskeletal ultrasound in rheumatology
Attendees will learn about new training developments
Attendees will be updated in the latest research and direction of ultrasound in rheumatology
Attendees will have the opportunity to discuss and share local and national initiatives and projects
Musculoskeletal ultrasound in paediatric rheumatology
Dr Madeleine Rooney, Musgrave Park Hospital, Belfast
Update on the sonoanatomy course
David Wright, Sunderland Royal Hospital, Sunderland
Training initiatives: The West Midlands experience
Dr Rainer Klocke, Dudley Hospitals, Dudley
Cutting edge in MUS research
Prof Peter Taylor, Imperial College London, London
SIG update and a review of BSR courses
Dr Cristina Estrach, Aintree University Hospital, Liverpool
Categories:
Poster tours:
Basic science
Basic science
Biology of bone, cartilage and connective tissue disease
Connective tissue diseases
Case reports
Cell receptor-ligand interaction, signalling, activation and apoptosis
Cytokines and inflammatory mediators
Education research
Epidemiology
Genetics
Health services research, economics and outcomes research
Rheumatoid arthritis: aetiopathogenesis and animal models
Sjögren’s syndrome and other connective tissue disorders
SLE and antiphospholipid syndrome
Vasculitis
11.30 - 13.00
Advances in psoriatic arthritis
Chairs: Prof Costantino Pitzalis, Barts and The London School of Medicine, London | Prof Roger Sturrock,
University of Glasgow, Glasgow
Aim:
Outcome 1:
To learn about psoriatic arthritis, from pathogenesis to novel therapies
Gain insights on how pathogenesis may contribute to diverse subset evolution both from the joint
and skin prospective
Understand the issues relating to establishing and running a specialist PsA clinic
Be informed on the latest therapeutic strategies to treat PsA
Outcome 2:
Outcome 3:
11.30
11.50
12.10
12.30
Advances in pathogenesis: the rheumatology view - what biological processes drive different
disease expressions in PsA?
Prof Costantino Pitzalis, Barts and The London School of Medicine, London
Advances in pathogenesis: the dermatology view
Prof Frank Nestle, St John’s Institute of Dermatology, London
Establishing a specialist PsA clinic: pitfalls and opportunities to improve patient care
Prof Neil McHugh, University of Bath, Bath
Advances in the treatment of PsA
Dr Philip Helliwell, University of Leeds, Leeds
11.30 - 13.00
Aim:
Outcome 1:
Outcome 2:
11.30
11.30 - 13.00
Aim:
Outcome 1:
Outcome 2:
11.30
11.40
12.00
12.20
12.40
11.30 - 13.00
Aim:
Outcome 1:
Outcome 2:
Outcome 3:
11.30
11.50
12.10
12:30
Ask the experts: Myositis
To discuss the evidence-based approach to myopathies
To evaluate complex cases of myopathy with specific reference to the current evidence
To discuss complex cases of myopathy
Trainees will present three cases to the experts and experts will present two to three slides
demonstrating the evidence to support the advice on best practice
Dr Hector Chinoy, University of Manchester, Manchester | Prof David Isenberg, UCL, London
Molecular mechanisms of disease: inflammatory arthritis I
To give attendees an overview and understanding of key issues in the molecular mechanisms
of inflammatory arthritis
Delegates will be aware of current dogma of molecular pathogenesis in inflammatory arthritis
Delegates will be aware of novel laboratory research in inflammatory arthritis
Keynote talk on inflammatory arthritis
Prof Michael Ehrenstein, UCL, London
ANTI-VCA and EBNA1 antibodies are produced in the rheumatoid synovium in the presence of ectopic
lymphoid structures and correlates with acpa production
Ms Cristina Croia, Queen Mary University of London, London
TLR9 induces tolerance to apoptotic cells and is responsible for inducing regulatory B cells
Dr Mohini Gray, University of Edinburgh, Edinburgh
Interleukin-27 receptor-deficient mice develop exacerbated inflammatory arthritis associated with
heightened t- and b- cell responses
Dr Gareth Jones, Cardiff University, Cardiff
Anti-TNF antibody therapy, but not TNF receptor blockade, induces IL-17 suppressing regulatory T cells
Ms Jenny McGovern, University College London, London
The management of upper limb dysfunction in people with rheumatoid arthritis
Chairs: Ms Jenny Ratcliffe, Macclesfield District General Hospital, Macclesfield | Prof Krysia Dziedzic, Keele
University, Keele
To provide an update on the evidence based rehabilitation of upper limb dysfunction in people with
rheumatoid arthritis (RA)
Attendees will gain an understanding of recent advances in the rehabilitation of upper limb dysfunction
in RA
Attendees will gain an insight into the current surgical management of upper limb dysfunction in RA
Attendees will gain an understanding of functional outcome measurement of upper limb dysfunction in RA
Current surgical management of the rheumatoid hand and wrist: indications and outcomes
Prof Jagdeep Nanchahal, Imperial College London, London
Hand and upper limb function assessment in rheumatoid arthritis
Mrs Catherine Ball, Imperial College London, London
Exercise therapy in the management of upper limb dysfunction in rheumatoid arthritis: results from a
randomised controlled trial
Dr Lindsay Bearne, King’s College London, London
The role of upper limb splinting in the management of people with rheumatoid arthritis
Dr Jo Adams, University of Southampton, Southampton
Event update | 30
Thursday 3 May 2012
11.30 - 13.00
11.30
11.45
12.00
12.15
12.30
12.45
11.30 - 13.00
Aim:
Outcome 1:
Outcome 2:
Outcome 3:
11.30
11.30 - 13.00
Aim:
Outcome 1:
Outcome 2:
Outcome 3:
11.30
11.45
12.00
12.15
12.30
12.45
Oral abstracts: Education
NRAS workwise workshops online resources: tools for people with RA to help them remain in the
workplace/get back to work
Mrs Clare Jacklin, National Rheumatoid Arthritis Society, Maidenhead
Designing virtual patients for musculoskeletal education: a grounded theory qualitative study
Dr Jes Bateman, University Hospitals Coventry and Warwickshire NHS Trust, Coventry
Have you been to Capri? www.capri.scot.nhs.uk early results of a clinic for arthritis patients in remission
on the internet
Dr Helen Harris, NHS Fife, Kirkcaldy
The evaluation of an arthritis education outreach programme to black and minority ethnic communities
Mrs Chandrika Gordhan, University of Birmingham, Birmingham
Patient experiences, attitudes and expectations towards receiving information about anti-TNF: a
qualitative study
Dr Paul Arkell, Keele University, Keele
National Rheumatoid Arthritis Society survey: impact of RA on the fily
Mrs Clare Jacklin, National Rheumatoid Arthritis Society, Maidenhead
SIG: Osteoporosis
To discuss the management of acute and chronic vertebral fractures for allied health professionals
To increase knowledge for allied health care professionals, especially nurses, physiotherapist and
occupational therapists of acute vertebral fracture management. Focusing on pain relief and
conservative methods of pain relief
To increase knowledge and awareness of management of chronic vertebral fracture and further
fracture prevention. Suitable for all allied health professionals including dietician, pharmacists,
podiatrists etc
To discuss the role of allied health care professionals within various fracture liason service models,
vertebral pain mangement and prevention of further fracture
The management of pain and chronic vertebral fracture and role within fracture liaison service
Cathy Churchman, Weston General Hospital, Weston-super-Mare
Rachel Lewis MCSP, North Bristol NHS Trust, Bristol
SIG: Foot and ankle
To provide an update on current developments in the foot and ankle with an emphasis on
degenerative disorders
To set out the current areas of research activity in foot and ankle research relating to OA
To provide a state of the art review of current knowledge
To provide a forum to identify future research directions and explore collaborations
Researching foot osteoarthritis in primary care
Dr Edward Roddy, Keele University
Foot outcomes from the Chingford cohort study of 1,000 women over 22 years
Dr Catherine Bowen, University of Southampton
Foot modeling in degenerative disease and its effect on biomechanical response to interventions
Dr Richard Jones, University of Salford
Modeling function in barefoot and shod conditions
Dr Jill Halstead, University of Leeds
Clinical and biomechanical foot assessments and knee OA in the COASt (Clinical Outcomes in
knee arthroplasty) study
Ms Lucy Gates, University of Southampton
Discussion
13.00 - 14.00
Exhibition | Lunch
13.00 - 14.00
RATS AGM
13.00 - 14.00
NICE and NHS Evidence and the information revolution
Aim:
Outcome 1:
Outcome 2:
Outcome 3:
Outcome 4:
13.00
14.00 - 15.30
Aim:
Outcome 1:
14.00
14.45
14.00 - 15.30
Aim:
Outcome 1:
Outcome 2:
Outcome 3:
14.00
14.20
14.40
15.00
14.00 - 15.30
Aim:
Outcome 1:
Outcome 2:
To demonstrate the key features of NHS Evidence and lead a discussion around further development
opportunities for the service
Delegates will be able to see how features of the site work and identify what will be useful to them
Delegates will be able to discuss any future ideas/developments that could be made around their needs
Delegates will learn about the practical QIPP examples that are available and learn how to submit
their own case studies
Delegates will have more confidence in using the resource in their work around decision-making
processes
Presentation and discussion facilitation
NICE speaker, Manchester
Rheumatology and the NHS
To update trainees on political changes in the NHS
To review the NHS changes as they affect rheumatology and trainees, from both primary and secondary
care perspectives
A year in politics: an update on political influences on rheumatology and its trainees
Dr Chris Deighton, Derbyshire Royal Infirmary, Derby
Changes in the NHS: a rheumatology provider’s perspective
Dr Alan Nye, Pennine MSK Partnership, Manchester
Improving work participation: new developments in reducing work absence for people with
musculoskeletal conditions
Chairs: Dr Ross Wilkie, Keele University, Keele | Mrs Victoria Chamberlain, Trafford Healthcare Trust,
Manchester
To provide delegates with an overview of recent advances in approaches and future plans to reduce
work absence for people with musculoskeletal conditions
Attendees have a clear understanding of the importance of supporting people with arthritis / MSDs
in remaining and returning to work, and of the role of health professionals in this
Attendees learn about practical tools (e.g. the fit-note) and examples of best practice in supporting
people with arthritis / MSDs in remaining and returning to work
Attendees are aware of further developments in policy and practice to reduce work absence
What is next for musculoskeletal conditions and work?
Prof Dame Carol Black, Department for Work and Pensions, London
What has the “fit-note” done for us? Reflections on the impact on work absence and disability
Dr Bill Gunneyon, Department for Work and Pensions, London
Rheumatology and work: evolving practice
Dr David Walker, Freeman Hospital, Newcastle upon Tyne
Reducing work absence for people with musculoskeletal conditions: the barriers that stop me working!
Ms Rosemarie Buttery, Arthritis Care, London
Molecular mechanisms of disease: inflammatory arthritis II
To give attendees an overview and understanding of key issues in the molecular mechanisms
of inflammatory arthritis
Delegates will be aware of current dogma of molecular pathogenesis in inflammatory arthritis
Delegates will be aware of novel laboratory research in inflammatory arthritis
Event update | 32
Thursday 3 May 2012
14.00
14.15
14.30
14.45
15.00
15.15
14.00 - 15.30
Aim:
Outcome 1:
Outcome 2:
Outcome 3:
14.00
14:25
14:50
14.00 - 15.30
14.00
14.15
14:30
14:45
15:00
15:15
Inhibition of NAMPT (PBEF/Visfatin) decreases the ability of human neutrophils to generate reactive
oxidants, but does not impair bacterial killing
Ms Kate Roberts, University of Liverpool, Liverpool
Neutrophil microparticles as potential novel effectors of joint disease
Ms Sarah Headland, Barts and the London School of Medicine and Dentistry, London
The mesenchymal stromal cell marker CD248 regulates inflammatory arthritis and bone formation
Dr Amy Naylor, University of Birmingham, Birmingham
Resolvin D1 limits PMN recruitment to inflammatory loci: receptor dependent bioactions
Dr Lucy Norling, Barts and The London Medical School, London
Dual specificity phosphatase 1 is a crucial negative regulator of inflammatory osteolysis and a mediator
of therapeutic effects of dexamethasone in collagen-induced arthritis
Ms Youridies Vattakuzhi, Kenndy Institute of Rheumatology, London
The regulation of arthritic bone erosions by IL-10
Dr Claire Greenhill, Cardiff University, Cardiff
What’s new in ankylosing spondylitis pathogenesis, assessment and treatment
Chairs: Prof Paul Bowness, Nuffield Orthopaedic Centre NHS Trust, Oxford | Dr Jonathan Packham, University
Hospital of North Staffordshire, Stoke on Trent
To give attendees an overview of new developments in the genetics, pathogenesis and treatment
of ankylosing spondylitis
Delegates will be aware the genetic contribution and pathogenic theories of ankylosing spondylitis
pathogenesis
Delegates will be able to describe the new ASA criteria for Axial SpA and the ASDAS
Delegates will be able to describe the critically evaluate the efficacies of new treatments for
ankylosing spondylitis
Overview of ankylosing spondylitis genetics and pathogenesis
Prof Paul Bowness, Nuffield Orthopaedic Centre NHS Trust, Oxford
What’s new in the clinical assessment of AS?
Prof Désirée van der Heijde, Leiden University Medical Center, Leiden, The Netherlands
New therapies for ankylosing spondylitis, targeting the Th17 pathway?
Prof Dominique Baeten, University of Amsterdam, Amsterdam, The Netherlands
Oral abstracts: Genetics
Global gene expression analysis of dedifferentiated chondrocytes
Mr Alan Mueller, University of Liverpool, Liverpool
Largest UK rheumatoid arthritis genome wide association study to date of 8,300 samples strengthens
confirmed loci and highlights more potential RA genetic risk factors
Dr Gisela Orozco, University of Manchester, Manchester
Fine mapping in over 14,000 rheumatoid arthritis cases and 18,500 controls refine associations to
known loci, indicate multiple independent affects and reveal novel associations
Prof Jane Worthington, The University of Manchester, Manchester
Investigation of idiopathic inflammatory myopathy for shared genetic risk factors with other autoimmune
disorders
Dr Meghna Jani, Salford Royal NHS Foundation Trust, Manchester
Analysis of the immunochip in a large cohort of oligo- and polyarthritis juvenile idiopathic arthritis cases
confirms previous and identifies novel associations
Dr Joanna Cobb, University of Manchester, Manchester
Genome-wide association study of methotrexate response identifies novel genes in a large cohort of
European juvenile idiopathic arthritis cases
Dr Joanna Cobb, University of Manchester, Manchester
14.00 - 15.30
Aim:
Outcome 1:
Outcome 2:
Outcome 3:
14.00
14.40
15.00
14.00 - 15.30
Aim:
Outcome 1:
Outcome 2:
Outcome 3:
14.00
14.05
14.20
14.40
15.20
15.30 - 17.00
15.30
15.40
16.00
16.20
16.40
17.00
SIG: Education
To provide an update on Arthritis Research UK educational developments over the last 12 months
Participants will understand (and participate in) the Arthritis Research UK tool for evalution of online
learning resources
Participants will be informed of the results of a study of CPD activities among rheumatology nurses
and allied health professionals
The opportunity for participants to discuss work in progress: educational developments or research
Development of a tool to evaluate online learning resources in rheumatology
Dr David Walker, Newcastle upon Tyne Hospitals Trust, Newcastle upon Tyne and
Dr Tom Margham, Arthritis Research UK
Results of a survey of rheumatology nurses and allied health professionals regarding CPD activities:
the service constraints of NHS practice?
Dr Sarah Ryan, Dept of Rheumatology, Haywood Hospital, Stoke-on-Trent
Open forum of educational developments
Prof Andrew Hassell, Keele University School of Medicine and Haywood Hospital, Keele
SIG: Osteoarthritis
To reflect on achievements of the OA CSG over the first four years and learn from other CSGs in shaping
future strategy
Know the strategy, submission and review processes of the Arthritis Research UK OA Clinical Studies Group
Learn how to become involved in ongoing studies
Have had the opportunity to network with other researchers and discuss research ideas
Introduction and welcome
Dr Fraser Birrell, Newcastle University, Newcastle upon Tyne
Progress of the Inflammatory Arthritis CSG
Prof John Isaacs, Newcastle University, Newcastle upon Tyne
Clinical Studies Group for OA and Related Disorders strategy
Prof Philip Conaghan, University of Leeds, Leeds
Translating ideas into action and results: group work
Hand OA
Facilitator: Dr Krysia Dziedzic, Keele University, Keele
Knee OA
Facilitator: Dr George Peat, Keele University, Keele
Hip OA
Facilitator: to be confirmed
Question and answer
SIG: Spondyloarthropathy
Welcome and Introduction
Prof Dennis McGonagle, University of Leeds, Leeds and Dr Raj Sengupta, The Royal National Hospital for
Rheumatic Diseases, Bath
Quality indicators for SpA in the UK
Pitfalls with diagnosis in spinal MRI scans
Dr Alex Bennett, Guys and St Thomas’ Teaching Hospitals, London,
IL12/23 p40 monoclonal antibody therapy in psoriatic disease: where are we?
The transition between psoriasis and arthritis: an imaging perspective
End of meeting
Event update | 34
Conference registration
Please note all prices shown include VAT
Delegate type
One day
Two day
Whole conference
*Early
Late
*Early
Late
*Early
Late
BSR Member
£102.00
£147.90
£204.00
£295.80
£260.10
£377.15
BSR RATS
£71.40
£103.53
£142.80
£207.06
£182.07
£264.00
BSR non member
£147.90
£214.46
£295.80
£428.91
£377.15
£546.86
BHPR Member
£60.00
£87.00
£120.00
£174.00
£153.00
£221.85
BHPR non member
£87.00
£126.15
£174.00
£252.30
£198.90
£288.41
**Reduced BSR Member
£61.20
£88.74
£122.40
£177.48
£156.06
£226.29
**Non-clinical scientists/Students
£42.00
£42.00
£84.00
£84.00
£126.00
£126.00
ARMA
£42.00
£42.00
£84.00
£84.00
£126.00
£126.00
* Any registrations received on or before the early bird deadline – Friday 3 February 2012 –
will be processed at the early rate.
** To see how to qualify for this rate, please visit the website www.rheumatology.org.uk/registration
Registration package
Registration includes:
Entry to the scientific sessions of your choice on the days for which you have registered
Entry to the Exhibition
Delegate bag with conference programme and abstracts
Lunch and refreshments
Welcome reception (for those registered for Tuesday and/or Wednesday)
Register online now
Registering for Rheumatology 2012 is easy. Simply visit www.rheumatology.org.uk/conference to book your place at the
UK’s leading rheumatology event. If you wish to pay for your registration via invoice, you can request an invoice online.
Please note that all registration fees must be paid in full before we can issue you with your delegate badge.
Online registration closes at 17.00 on Friday 27 April 2012.
On-site registration
If there are places available, you can register for the conference on-site. Please note that registration rates will be higher
on-site as they will include an additional admin fee. We are not able to issue invoices on-site. Why not save money,
avoid the queues at registration and guarantee your place by booking online now at
www.rheumatology.org.uk/conference
Cancellation and amendments
If you cancel in writing on or before 30 March 2012 you will receive a refund minus an admin fee of £20. No fees will
be refunded for any cancellations received after 30 March 2012 under any circumstances. Name change amendments
are accepted at our discretion and carry a £20 admin fee. Please see our website for full terms and conditions.
Exhibition
It is with great pleasure we announce Rheumatology 2012’s exhibition, which will
run alongside the conference, attracting leading industry partners in the field of
rheumatology. We expect a number of companies specialising in biologic drugs,
medical clinic software, diagnostic tools, ultrasound machines, medical therapies,
biotechnology and therapeutic products alongside principal patient charities,
educational providers and publishers.
The exhibition takes place in Hall 5 at the SECC
where you can meet with your industry colleagues
and learn directly about their products and services.
You are invited to visit the exhibition at the following
times:
Tuesday
01 May 2012
Thursday
03 May 2012
09.00-17.00
09.00-17.00
09.00-14.15
Industry supported sympoisa
Rheumatology 2012 will once again host the
popular industry supported symposia. These
educational sessions, scheduled during the
conference, are free of charge, allow you the
opportunity to listen to exciting topics, experience
innovative formats and network.
Sessions will be hosted within the SECC, with a
maximum of two symposia running concurrently on
the following dates:
Pfizer
Tuesday 01 May | 18.00-19.30
Bristol Myers Squibb
Wednesday 02 May | 07.30-09.00
Cellestis GmbH
Abbott
Roche
Abbott
Thursday 03 May | 07.30-09.00
Please visit www.rheumatology.org.uk/conference
for further details.
Exhibitors currently confirmed:
A. Algeo
ARMA
Arthritis Care
Arthritis Research UK
4S Information Systems
Abbott
BARC
British Health Professionals in Rheumatology
Bristol Myers Squibb
British Society for Rheumatology
BSR Biologics Register
BSSA
Central Homecare
Eli Lilly
Fibromyalgia Association
GlaxoSmithKline
Grunenthal
Healthcare at Home
Lupus UK
Medac UK
Merck Sharpe and Dohme
Miltenyi Biotec Ltd
NASS
NRAS
Oxford University Press
Oxford Diagnostic Laboratories
PMR & GCA
Pfizer
PSALV
Pulmonary Hypertension Association UK
RCN
Roche Products Ltd
Scleroderma Society
Servier Lab Ltd
UCB
Wisepress
‘Networking with colleagues in rheumatology is
invaluable and the conference is the perfect
opportunity to do just that’ Delegate
You have told us that networking can be one of the most valuable activities at the
conference. We have some great networking opportunities to ensure you get the
most from your conference experience
Tuesday 1 May, 19.45-21.00
President’s reception
The Presidents of BSR and BHPR invite you to join them
and your fellow delegates to continue your discussions
from the day, catch up with colleagues and make new
contacts at this informal social event. This event will take
place at the adjacent Crowne Plaza Hotel
Drinks and canapés will be provided at this
excellent networking platform
The event is free to attend for registered conference
delegates.
Wednesday 2 May, 20.00-00.00
Conference dinner and ceilidh
Back by popular demand, the conference dinner promises
an exceptional evening of traditional Scottish food and
dancing.
Join us at Òran Mór for networking with colleagues at this
entertaining event.
20.00:
20.30:
22.00:
23.00:
Drinks reception
Dinner
Ceilidh
Further entertainment
Places are limited so be sure to book early.
Tickets are only £40 (Inc VAT)
BSR, Bride House, 18-20 Bride Lane, London EC4Y 8EE
Tel: +44 (0) 20 7842 0900 Fax: +44 (0) 20 7842 0901
Website: www.rheumatology.org.uk
A Charity registered in England and Wales
A Company limited by guarantee
VAT No: 404 5637 66
Company Reg. No: 3470316
Charity No: 1067124
®
MIX
From responsible
sources
FSC® TT-COC-002846
www.fsc.org

Update_Layout 1 - The British Society for Rheumatology

Transcription

Similar documents

Do you have joint pain? It could be Rheumatoid Arthritis.

08 - Rohrbasser - Electrophorese capillaire_projet PHARMELP

details - Jamia Millia Islamia

View paper - Romanian Neurosurgery

Adult onset Still`s disease

EMERGING TRENDS IN MECHANICAL ENGINEERING

European Congress of Internal Medicine

masinski fakultet skopje

44th CIRP Conference on Manufacturing Systems Program